Buchumschlag

Cardiac hematological malignancies: typical growth patterns, imaging features, and clinical outcome

Cardiac hematological malignancies (CHMs) are rare entities and comprise lymphoma, leukemic infiltration, and extramedullary manifestation of multiple myeloma. The aim of this work is to summarize typical growth patterns, imaging features, and outcome parameters of CHM. Overall, 12 cases from 4 cent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Voigt, Peter (VerfasserIn) , Weber, Marc-André (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2018
In: Angiology
Year: 2017, Jahrgang: 69, Heft: 2, Pages: 170-176
ISSN:1940-1574
DOI:10.1177/0003319717713581
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1177/0003319717713581
Volltext
Verfasserangaben:Peter Voigt, Susanne Wienbeck, Marc-André Weber, Noriko Oyama-Manabe, Maximilian Beimler, Stefan Schob, Thomas Kahn, Hans Jonas Meyer, Jan Frieso Randaxhe, and Alexey Surov
Beschreibung
Zusammenfassung:Cardiac hematological malignancies (CHMs) are rare entities and comprise lymphoma, leukemic infiltration, and extramedullary manifestation of multiple myeloma. The aim of this work is to summarize typical growth patterns, imaging features, and outcome parameters of CHM. Overall, 12 cases from 4 centers were reviewed retrospectively together with 604 cases from the literature. Cardiac hematological malignancies were mainly represented by B-cell lymphoma (70.0%). Other entities were rarer. Almost half of the patients showed involvement of multiple cardiac structures. Most commonly right atrium, right ventricle, pericardium, left atrium, and left ventricle were affected in decreased order of frequency. Cardiac hematological malignancies manifested with 3 growth patterns: intracaval masses, heart wall infiltration, and pericardial effusion. Several subtypes of CHM tended to present with different patterns. Clinical presentation is unspecific—frequent signs were dyspnea (54.6%), arrhythmias (30.5%), and thoracic pain (18.5%). Outcome of CHM is poor with mean survival of 283.6 days for leukemias, 260.1 days for T-cell non-Hodgkin lymphoma (NHL), 217.9 days for B-cell NHL, and 155.5 days for multiple myeloma.
Beschreibung:First published June 12, 2017
Gesehen am 06.09.2018
Beschreibung:Online Resource
ISSN:1940-1574
DOI:10.1177/0003319717713581

Ähnliche Einträge